UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

Dow Jones

03/02

By Adriano Marchese

UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective.

Shares traded 42% lower ahead of the morning bell at $9.

The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130.

Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain.

UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study.

The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 02, 2026 07:58 ET (12:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2616332185"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616332185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616332185?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616332185","market":"fut","top_or_hot":-1,"title":"UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective. \n</p>\n<p>\n  Shares traded 42% lower ahead of the morning bell at $9. \n</p>\n<p>\n  The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130. \n</p>\n<p>\n  Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain. \n</p>\n<p>\n  UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study. \n</p>\n<p>\n  The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 07:58 ET (12:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-02 20:58</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective. \n</p>\n<p>\n  Shares traded 42% lower ahead of the morning bell at $9. \n</p>\n<p>\n  The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130. \n</p>\n<p>\n  Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain. \n</p>\n<p>\n  UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study. \n</p>\n<p>\n  The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 02, 2026 07:58 ET (12:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富蘭克林生物科技新領域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2616332185","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616332185","pubTimestamp":1772456280,"columns":[{"name":"行業數據","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective.Shares traded 42% lower ahead of the morning bell at $9.The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130.Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain.UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study.The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to disc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"FDA称亨廷顿基因治疗数据不足，UniQure上市前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  UniQure shares fell in premarket trading Monday after the Food and Drug Administration said the company's data isn't strong enough to show its Huntington's disease gene therapy is effective. \n\n\n  Shares traded 42% lower ahead of the morning bell at $9. \n\n\n  The gene-therapy company said Monday that the FDA stated that it can't agree that data from the Phase I/II studies, compared with an external control, provide enough primary evidence of effectiveness required to support a marketing application for the drug AMT-130. \n\n\n  Huntington's disease is an inherited and progressive neurodegenerative disorder that is caused by faulty genes triggering the breakdown of nerve cells in the brain. \n\n\n  UniQure said the regulator is urging the company to run a more rigorous trial that includes randomized, double-blind, sham surgery-controlled study. \n\n\n  The company said it intends to keep working with the FDA on what a Phase III program should look like and plans to request a type B meeting in the second quarter of 2026 to discuss possible study designs. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:58 ET (12:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}